Effects of dehydroepiandrosterone on rat apolipoprotein AI gene expression in the human hepatoma cell line, HepG2.
Serum apolipoprotein AI (apoAI) levels correlate with the risk of developing atherosclerosis. Previous studies have suggested that dehydroepiandrosterone (DHEA) lowers high-density lipoprotein (HDL)-cholesterol levels. We investigated whether or not DHEA may lower HDL-cholesterol levels by suppressing apoAI gene transcription in hepatocytes. ApoAI mRNA levels, assessed by Northern blotting, were suppressed in HepG2 cells treated with DHEA (34%) (10 microg/mL) or testosterone (36%) (T, 1 microg/mL). Estradiol alone (E2, 1 microg/mL) had relatively little effect on apoAI mRNA levels, while E2 in combination with DHEA prevented a decrease in apoAI mRNA levels compared to DHEA alone. To determine whether these effects were due to changes in apoAI gene transcription, HepG2 cells were transfected with a plasmid carrying the full-length promoter of the rat apoAI gene ligated into a chloramphenicol acetyltransferase (CAT) reporter construct. The plasmid pCMV.SPORT-beta-gal was included in each transfection to normalize the data to transfection efficiency. Cells were then cultured in the presence or absence of DHEA (10 microg/mL), T (1 microg/mL), 17alpha-methyltestosterone (MTT, 1 microg/mL), 5alpha-dihydrotestosterone (DHT, 1 microg/mL), E2 (1 microg/mL), or a combination of DHEA plus E2, T plus E2, MTT plus E2, and DHT plus E2, for 24 hours. CAT activity, relative to beta-galactosidase activity, was reduced by 19.6%, 57.6%, 38.6%, and 54.6% with DHEA, T, DHT, and MTT addition, respectively. E2 increased CAT activity by 43.8%. When the androgens (ie, DHEA, T, DHT, or MTT) were combined with E2, apoAI promoter activity was suppressed. We conclude, therefore, that androgens downregulate apoAI promoter activity in the presence or absence of E2. However, the changes in mRNA levels do not always reflect changes in promoter activity, suggesting that these steroids may have additional post-transcriptional effects on steady-state apoAI mRNA levels. It remains to be established if the transcriptional effects we observed are mediated through an androgen response element.
Deleon
Mary Jeanne
MJ
Division of Endocrinology, Diabetes, and Metabolism, Saint Louis University School of Medicine, St Louis, MO 63104, USA.
Horani
Mohamad H
MH
Haas
Michael J
MJ
Wong
Norman C W
NC
Mooradian
Arshag D
AD
D000818:Animals; D016632:Apolipoprotein A-I / Q000235:genetics*; D003687:Dehydroepiandrosterone / Q000494:pharmacology*; D013196:Dihydrotestosterone / Q000494:pharmacology; D015536:Down-Regulation; D004958:Estradiol / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects*; D012739:Gonadal Steroid Hormones; D006801:Humans; D008777:Methyltestosterone / Q000494:pharmacology; D011401:Promoter Regions, Genetic / Q000187:drug effects / Q000502:physiology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D013739:Testosterone / Q000494:pharmacology; D045165:Testosterone Congeners / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D016632:Apolipoprotein A-I; D012739:Gonadal Steroid Hormones; D012333:RNA, Messenger; D045165:Testosterone Congeners; D013196:Dihydrotestosterone; D013739:Testosterone; D003687:Dehydroepiandrosterone; D004958:Estradiol; D008777:Methyltestosterone